218 related articles for article (PubMed ID: 23872400)
1. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression.
Leggio GM; Salomone S; Bucolo C; Platania C; Micale V; Caraci F; Drago F
Eur J Pharmacol; 2013 Nov; 719(1-3):25-33. PubMed ID: 23872400
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
Duric V; Banasr M; Franklin T; Lepack A; Adham N; Kiss B; Gyertyán I; Duman RS
Int J Neuropsychopharmacol; 2017 Oct; 20(10):788-796. PubMed ID: 28531264
[TBL] [Abstract][Full Text] [Related]
3. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
4. Involvement of DA D3 Receptors in Structural Neuroplasticity of Selected Limbic Brain Circuits: Possible Role in Treatment-Resistant Depression.
Merlo Pich E; Cavalleri L; Toma C; Collo G
Curr Top Behav Neurosci; 2023; 60():73-87. PubMed ID: 35538302
[TBL] [Abstract][Full Text] [Related]
5. The Dopamine Receptor D3 Regulates Lipopolysaccharide-Induced Depressive-Like Behavior in Mice.
Wang J; Jia Y; Li G; Wang B; Zhou T; Zhu L; Chen T; Chen Y
Int J Neuropsychopharmacol; 2018 May; 21(5):448-460. PubMed ID: 29390063
[TBL] [Abstract][Full Text] [Related]
6. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
7. Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response.
Dremencov E; Weizmann Y; Kinor N; Gispan-Herman I; Yadid G
Curr Drug Targets; 2006 Feb; 7(2):165-75. PubMed ID: 16475958
[TBL] [Abstract][Full Text] [Related]
8. PPARα modulation of mesolimbic dopamine transmission rescues depression-related behaviors.
Scheggi S; Melis M; De Felice M; Aroni S; Muntoni AL; Pelliccia T; Gambarana C; De Montis MG; Pistis M
Neuropharmacology; 2016 Nov; 110(Pt A):251-259. PubMed ID: 27457507
[TBL] [Abstract][Full Text] [Related]
9. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.
Peciña M; Sikora M; Avery ET; Heffernan J; Peciña S; Mickey BJ; Zubieta JK
Eur Neuropsychopharmacol; 2017 Oct; 27(10):977-986. PubMed ID: 28870407
[TBL] [Abstract][Full Text] [Related]
10. Effects of immobilization stress on emotional behaviors in dopamine D3 receptor knockout mice.
Xing B; Liu P; Jiang WH; Liu F; Zhang H; Cao GF; Chen T; Dang YH
Behav Brain Res; 2013 Apr; 243():261-6. PubMed ID: 23357086
[TBL] [Abstract][Full Text] [Related]
11. Current drug treatments targeting dopamine D3 receptor.
Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
[TBL] [Abstract][Full Text] [Related]
12. Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.
Jastrzębska-Więsek M; Siwek A; Partyka A; Antkiewicz-Michaluk L; Michaluk J; Romańska I; Kołaczkowski M; Wesołowska A
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):839-49. PubMed ID: 27106213
[TBL] [Abstract][Full Text] [Related]
13. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.
Dremencov E; Newman ME; Kinor N; Blatman-Jan G; Schindler CJ; Overstreet DH; Yadid G
Neuropharmacology; 2005 Jan; 48(1):34-42. PubMed ID: 15617725
[TBL] [Abstract][Full Text] [Related]
14. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
Dhir A; Kulkarni SK
Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D3 receptor antisense oligodeoxynucleotide potentiates imipramine-induced dopaminergic behavioural supersensitivity.
D'Aquila PS; Panin F; Castelli MP; Serra G
Behav Pharmacol; 2006 Mar; 17(2):101-6. PubMed ID: 16495718
[TBL] [Abstract][Full Text] [Related]
16. [Antidepressant effects of dopamine agonists. Experimental and clinical findings].
Lemke MR
Nervenarzt; 2007 Jan; 78(1):31-8. PubMed ID: 17187269
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test.
Basso AM; Gallagher KB; Bratcher NA; Brioni JD; Moreland RB; Hsieh GC; Drescher K; Fox GB; Decker MW; Rueter LE
Neuropsychopharmacology; 2005 Jul; 30(7):1257-68. PubMed ID: 15688083
[TBL] [Abstract][Full Text] [Related]
19. Suppression of reward-induced dopamine release in the nucleus accumbens in animal models of depression: Differential responses to drug treatment.
Minami S; Satoyoshi H; Ide S; Inoue T; Yoshioka M; Minami M
Neurosci Lett; 2017 May; 650():72-76. PubMed ID: 28432029
[TBL] [Abstract][Full Text] [Related]
20. Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse.
Amiri S; Amini-Khoei H; Mohammadi-Asl A; Alijanpour S; Haj-Mirzaian A; Rahimi-Balaei M; Razmi A; Olson CO; Rastegar M; Mehdizadeh M; Zarrindast MR
Physiol Behav; 2016 Sep; 163():107-114. PubMed ID: 27143252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
